Table 1 Characteristics and evolution of acromegalic and control patients (absolute values and percentages)
From: Acromegaly and thyroid cancer: analysis of evolution in a series of patients
Patients | Acro (n = 23) | Controls (n = 92) | p-value |
|---|---|---|---|
Gender [Female: n (%)] | 18 (78.3) | 82 (89.1) | 0.29 |
Mean age at DTC diagnosis (years ± SD) | 49.3 ± 13.9 | 47.5 ± 16.5 | 0.31 |
Insulin resistance [n (%)] | 9 (39.1) | 10 (10.9) | 0.003 |
History of other cancer [n (%)] | 2 (8.7) | 3 (3.3) | 0.56 |
Histologya [n (%)] | |||
clPTC | 16 (69.6) | 73 (79.3) | 0.43 |
fvPTC | 7 (30.4) | 19 (20.7) | |
Mean tumor size [mm, (range)] | 15.2 (4–35) | 14.6 (3–60) | 0.76 |
Lymphadenectomy [n (%)] | 8 (34.8) | 15 (16.3) | 0.09 |
Node metastases [n (%)] | 5 (62.5) | 10 (66.7) | 1 |
Radioiodine ablation [n (%)] | 21 (91.3) | 63 (68.5) | 0.052 |
Median iodine dose [mCi, (range)] | 100 (30–300) | 100 (30–150) | 0.53 |
Median time of follow-up [months, (range)] | 36.5 (6–120) | 49.5 (6–219) | 0.14 |
Follow-up responseb [n (%)] | |||
NED | 19 (82.7) | 60 (65.2) | 0.36 |
Ind | 2 (8.7) | 22 (23.9) | |
BI | 1 (4.3) | 3 (3.3) | |
SI | 1 (4.3) | 7 (7.6) | |